| 1 |
Guo LW, Wang YK, Li SJ, Yin GT, Li D. Elevated Fibroblast Growth Factor 23 Impairs Endothelial Function through the NF-κB Signaling Pathway. J Atheroscler Thromb 2023;30:138-49. [PMID: 35314565 DOI: 10.5551/jat.63460] [Reference Citation Analysis]
|
| 2 |
Wu Q, Ye Z, Zhou C, Liu M, Zhang Y, Zhang Z, He P, Li R, Li H, Yang S, Zhang Y, Jiang J, Nie J, Liu C, Qin X. A U-shaped association between dietary phosphorus intake and new-onset hypertension: a nationwide cohort study in China. Am Heart J 2023;259:21-9. [PMID: 36690241 DOI: 10.1016/j.ahj.2023.01.013] [Reference Citation Analysis]
|
| 3 |
Negah SS, Forouzanfar F. Dual Role of Fibroblast Growth Factor Pathways in Sleep Regulation. Endocr Metab Immune Disord Drug Targets 2023;23:63-9. [PMID: 35927892 DOI: 10.2174/1871530322666220802161031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Miceli G, Basso MG, Rizzo G, Pintus C, Tuttolomondo A. The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. Int J Mol Sci 2022;23. [PMID: 36499242 DOI: 10.3390/ijms232314914] [Reference Citation Analysis]
|
| 5 |
Liu Y, Chen Q, Li Y, Bi L, He Z, Shao C, Jin L, Peng R, Zhang X. Advances in FGFs for diabetes care applications. Life Sci 2022;:121015. [PMID: 36179818 DOI: 10.1016/j.lfs.2022.121015] [Reference Citation Analysis]
|
| 6 |
Buyukdemirci S, Oguz EG, Cimen SG, Sahin H, Cimen S, Ayli MD. Vitamin D deficiency may predispose patients to increased risk of kidney transplant rejection. World J Transplant 2022; 12(9): 299-309 [DOI: 10.5500/wjt.v12.i9.299] [Reference Citation Analysis]
|
| 7 |
Lee S, Kim S. Effects of Normal Reference Range of Phosphorus and Corresponding PTH on Endothelial Function in CKD Patients. Front Med 2022;9. [DOI: 10.3389/fmed.2022.935977] [Reference Citation Analysis]
|
| 8 |
Litvinova MS, Khaisheva LA, Shlyk SV, Aboyan IA. Vascular calcification and fibroblast growth factor in resistant hypertension. Arter gipertenz 2022;28:157-166. [DOI: 10.18705/1607-419x-2022-28-2-157-166] [Reference Citation Analysis]
|
| 9 |
Volk C, Schmidt B, Brandsch C, Kurze T, Schlegelmilch U, Grosse I, Ulrich C, Girndt M, Stangl GI. Acute Effects of an Inorganic Phosphorus Additive on Mineral Metabolism and Cardiometabolic Risk Factors in Healthy Subjects. J Clin Endocrinol Metab 2022;107:e852-64. [PMID: 34448875 DOI: 10.1210/clinem/dgab635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Eitner F, Richter B, Schwänen S, Szaroszyk M, Vogt I, Grund A, Thum T, Heineke J, Haffner D, Leifheit-nestler M. Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy. Front Cell Dev Biol 2022;9:791479. [DOI: 10.3389/fcell.2021.791479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Harlacher E, Wollenhaupt J, Baaten CCFMJ, Noels H. Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review. Int J Mol Sci 2022;23:531. [PMID: 35008960 DOI: 10.3390/ijms23010531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Chen H, Pan J, Lu W, Wu C, Tseng C. Prazosin improves neurogenic acute heart failure through downregulation of fibroblast growth factor 23 in rat hearts. Chin J Physiol 2022;65:179. [DOI: 10.4103/cjp.cjp_9_22] [Reference Citation Analysis]
|
| 13 |
Ebert T, Stenvinkel P. Premature vascular aging and senescence in chronic kidney disease. Regenerative Nephrology 2022. [DOI: 10.1016/b978-0-12-823318-4.00012-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Nashawi M, Ahmed MS, Amin T, Abualfoul M, Chilton R. Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy. World J Cardiol 2021;13:676-94. [PMID: 35070111 DOI: 10.4330/wjc.v13.i12.676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 15 |
Deng J, Liu Y, Liu Y, Li W, Nie X. The Multiple Roles of Fibroblast Growth Factor in Diabetic Nephropathy. J Inflamm Res 2021;14:5273-90. [PMID: 34703268 DOI: 10.2147/JIR.S334996] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 16 |
Alderson HV, Chinnadurai R, Ibrahim ST, Asar O, Ritchie JP, Middleton R, Larsson A, Diggle PJ, Larsson TE, Kalra PA. Longitudinal change in c-terminal fibroblast growth factor 23 and outcomes in patients with advanced chronic kidney disease. BMC Nephrol 2021;22:329. [PMID: 34600515 DOI: 10.1186/s12882-021-02528-2] [Reference Citation Analysis]
|
| 17 |
Zhang R, Wang SY, Yang F, Ma S, Lu X, Kan C, Zhang JB. Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review). Exp Ther Med 2021;22:1159. [PMID: 34504604 DOI: 10.3892/etm.2021.10593] [Reference Citation Analysis]
|
| 18 |
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet 2021;398:786-802. [PMID: 34175022 DOI: 10.1016/S0140-6736(21)00519-5] [Cited by in Crossref: 239] [Cited by in F6Publishing: 164] [Article Influence: 119.5] [Reference Citation Analysis]
|
| 19 |
Kusmic C, Vizzoca A, Taranta M, Tedeschi L, Gherardini L, Pelosi G, Giannetti A, Tombelli S, Grimaldi S, Baldini F, Domenici C, Trivella MG, Cinti C. Silencing Survivin: a Key Therapeutic Strategy for Cardiac Hypertrophy. J Cardiovasc Transl Res 2021. [PMID: 34409583 DOI: 10.1007/s12265-021-10165-1] [Reference Citation Analysis]
|
| 20 |
van der Vaart A, Yeung SMH, van Dijk PR, Bakker SJL, de Borst MH. Phosphate and fibroblast growth factor 23 in diabetes. Clin Sci (Lond) 2021;135:1669-87. [PMID: 34283205 DOI: 10.1042/CS20201290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 21 |
McCarty MF, Lerner A, DiNicolantonio JJ, Iloki-Assanga SB. High Intakes of Bioavailable Phosphate May Promote Systemic Oxidative Stress and Vascular Calcification by Boosting Mitochondrial Membrane Potential-Is Good Magnesium Status an Antidote? Cells 2021;10:1744. [PMID: 34359914 DOI: 10.3390/cells10071744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Memmos E, Papagianni A. New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients. Curr Vasc Pharmacol 2021;19:55-62. [PMID: 32310050 DOI: 10.2174/1570161118666200420102100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Vergaro G, Aimo A, Taurino E, Del Franco A, Fabiani I, Prontera C, Masotti S, Musetti V, Emdin M, Passino C. Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. Int J Cardiol 2021;336:98-104. [PMID: 34019969 DOI: 10.1016/j.ijcard.2021.05.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Kurpas A, Supeł K, Idzikowska K, Zielińska M. FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease. Dis Markers 2021;2021:8821292. [PMID: 34055103 DOI: 10.1155/2021/8821292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Graves JM, Vallejo JA, Hamill CS, Wang D, Ahuja R, Patel S, Faul C, Wacker MJ. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. Am J Physiol Heart Circ Physiol 2021;320:H2283-94. [PMID: 33929896 DOI: 10.1152/ajpheart.00798.2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 26 |
Hu CT, Shao YD, Liu YZ, Xiao X, Cheng ZB, Qu SL, Huang L, Zhang C. Oxidative stress in vascular calcification. Clin Chim Acta 2021;519:101-10. [PMID: 33887264 DOI: 10.1016/j.cca.2021.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 27 |
Hu W, Jiang S, Liao Y, Li J, Dong F, Guo J, Wang X, Fei L, Cui Y, Ren X, Xu N, Zhao L, Chen L, Zheng Y, Li L, Patzak A, Persson PB, Zheng Z, Lai EY. High phosphate impairs arterial endothelial function through AMPK-related pathways in mouse resistance arteries. Acta Physiol (Oxf) 2021;231:e13595. [PMID: 33835704 DOI: 10.1111/apha.13595] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 28 |
Kirchler C, Husar-Memmer E, Rappersberger K, Thaler K, Fritsch-Stork R. Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review. Autoimmun Rev 2021;20:102794. [PMID: 33722754 DOI: 10.1016/j.autrev.2021.102794] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 29 |
Ishigami J, Grams ME, Michos ED, Lutsey PL, Matsushita K. 25-hydroxyvitamin D, Fibroblast Growth Factor 23, and Risk of Acute Kidney Injury Over 20 Years of Follow-Up. Kidney Int Rep 2021;6:1299-308. [PMID: 34013108 DOI: 10.1016/j.ekir.2021.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Wojtaszek E, Oldakowska-Jedynak U, Kwiatkowska M, Glogowski T, Malyszko J. Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation. Oxid Med Cell Longev 2021;2021:6651367. [PMID: 33628373 DOI: 10.1155/2021/6651367] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 31 |
Vila Cuenca M, Hordijk PL, Vervloet MG. Most exposed: the endothelium in chronic kidney disease. Nephrol Dial Transplant 2020;35:1478-87. [PMID: 31071222 DOI: 10.1093/ndt/gfz055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 32 |
Vaidya R, Church A, Karim L. Effect of type 2 diabetes on bone cell behavior. The Science, Etiology and Mechanobiology of Diabetes and its Complications 2021. [DOI: 10.1016/b978-0-12-821070-3.00001-5] [Reference Citation Analysis]
|
| 33 |
Perwad F, Egli-spichtig D. The experimental detection of FGF23 responsiveness in target organs. Fibroblast Growth Factor 23 2021. [DOI: 10.1016/b978-0-12-818036-5.00008-2] [Reference Citation Analysis]
|
| 34 |
Fukumoto S. Klotho—the discovery of the FGF23 coreceptor. Fibroblast Growth Factor 23 2021. [DOI: 10.1016/b978-0-12-818036-5.00022-7] [Reference Citation Analysis]
|
| 35 |
Musgrove J, Grabner A. Klotho-independent actions of FGF23—targets, signal transduction, and cellular effects. Fibroblast Growth Factor 23 2021. [DOI: 10.1016/b978-0-12-818036-5.00001-x] [Reference Citation Analysis]
|
| 36 |
Serna J, Bergwitz C. Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging. Nutrients 2020;12:E3001. [PMID: 33007883 DOI: 10.3390/nu12103001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 37 |
Neyra JA, Hu MC, Moe OW. Fibroblast Growth Factor 23 and αKlotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications. Nephron 2020;144:665-72. [PMID: 32841947 DOI: 10.1159/000509856] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 38 |
Roumeliotis S, Mallamaci F, Zoccali C. Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. J Clin Med 2020;9:E2359. [PMID: 32718053 DOI: 10.3390/jcm9082359] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 20.7] [Reference Citation Analysis]
|
| 39 |
Six I, Flissi N, Lenglet G, Louvet L, Kamel S, Gallet M, Massy ZA, Liabeuf S. Uremic Toxins and Vascular Dysfunction. Toxins (Basel) 2020;12:E404. [PMID: 32570781 DOI: 10.3390/toxins12060404] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 40 |
Humalda JK, Yeung SMH, Geleijnse JM, Gijsbers L, Riphagen IJ, Hoorn EJ, Rotmans JI, Vogt L, Navis G, Bakker SJL, de Borst MH. Effects of Potassium or Sodium Supplementation on Mineral Homeostasis: A Controlled Dietary Intervention Study. J Clin Endocrinol Metab 2020;105:e3246-56. [PMID: 32506135 DOI: 10.1210/clinem/dgaa359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 41 |
Eisenga MF, De Jong MA, Leaf DE, Nolte IM, De Borst MH, Bakker SJL, Gaillard CAJM. Erythropoietin, Fibroblast Growth Factor 23, and Death After Kidney Transplantation. JCM 2020;9:1737. [DOI: 10.3390/jcm9061737] [Reference Citation Analysis]
|
| 42 |
Hu X, Yang L, Yu W, Pan W, Chen X, Li Q, Zhou J, Gu X. Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes. Diabetes Metab Syndr Obes 2020;13:1171-8. [PMID: 32368110 DOI: 10.2147/DMSO.S241348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 43 |
Anand S, Jagannathan R, Gupta R, Mohan S, Prabhakaran D, Wolf M. Fibroblast Growth Factor-23 and a Vegetarian Diet. J Ren Nutr 2020;30:503-8. [PMID: 32247648 DOI: 10.1053/j.jrn.2020.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 44 |
Ebert T, Pawelzik SC, Witasp A, Arefin S, Hobson S, Kublickiene K, Shiels PG, Bäck M, Stenvinkel P. Inflammation and Premature Ageing in Chronic Kidney Disease. Toxins (Basel) 2020;12:E227. [PMID: 32260373 DOI: 10.3390/toxins12040227] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 19.3] [Reference Citation Analysis]
|
| 45 |
Oakley CI, Vallejo JA, Wang D, Gray MA, Tiede-Lewis LM, Shawgo T, Daon E, Zorn G 3rd, Stubbs JR, Wacker MJ. Trimethylamine-N-oxide acutely increases cardiac muscle contractility. Am J Physiol Heart Circ Physiol 2020;318:H1272-82. [PMID: 32243768 DOI: 10.1152/ajpheart.00507.2019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 46 |
Bouma-de Krijger A, Vervloet MG. Fibroblast growth factor 23: are we ready to use it in clinical practice? J Nephrol 2020;33:509-27. [PMID: 32130720 DOI: 10.1007/s40620-020-00715-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 47 |
Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, Aziz NB, Elmariah S, Ngo D, Pajevic PD, Govea N, Kestenbaum BR, de Boer IH, Cheng Z, Christov M, Chun J, Leaf DE, Waikar SS, Tager AM, Gerszten RE, Thadhani RI, Clish CB, Jüppner H, Wein MN, Rhee EP. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest 2020;130:1513-26. [PMID: 32065590 DOI: 10.1172/JCI131190] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 48 |
Liu YC, Tsai JP, Wang LH, Lee MC, Hsu BG. Positive correlation of serum fibroblast growth factor 23 with peripheral arterial stiffness in kidney transplantation patients. Clin Chim Acta 2020;505:9-14. [PMID: 32070728 DOI: 10.1016/j.cca.2020.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Bouzina H, Hesselstrand R, Rådegran G. Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension. Pulm Circ 2019;9:2045894019895446. [PMID: 31908768 DOI: 10.1177/2045894019895446] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 50 |
Rauner M, Jähn K, Hemmatian H, Colditz J, Goettsch C. Cellular Contributors to Bone Homeostasis. Contemporary Cardiology 2020. [DOI: 10.1007/978-3-030-46725-8_16] [Reference Citation Analysis]
|
| 51 |
Disthabanchong S, Srisuwarn P. Mechanisms of Vascular Calcification in Kidney Disease. Adv Chronic Kidney Dis 2019;26:417-26. [PMID: 31831120 DOI: 10.1053/j.ackd.2019.08.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 52 |
Shi J, Fan J, Su Q, Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism. Front Endocrinol (Lausanne) 2019;10:703. [PMID: 31736870 DOI: 10.3389/fendo.2019.00703] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 53 |
Vervloet M. Modifying Phosphate Toxicity in Chronic Kidney Disease. Toxins (Basel). 2019;11:522. [PMID: 31505780 DOI: 10.3390/toxins11090522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 54 |
van de Wouw J, Broekhuizen M, Sorop O, Joles JA, Verhaar MC, Duncker DJ, Danser AHJ, Merkus D. Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets. Front Physiol 2019;10:1108. [PMID: 31551803 DOI: 10.3389/fphys.2019.01108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 55 |
Eisenga MF, Emans ME, van der Putten K, Cramer MJ, Diepenbroek A, Velthuis BK, Doevendans PA, Verhaar MC, Joles JA, Bakker SJL, Nolte IM, Braam B, Gaillard CAJM. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease. J Am Heart Assoc 2019;8:e011130. [PMID: 31423921 DOI: 10.1161/JAHA.118.011130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 56 |
Smith ER, Holt SG, Hewitson TD. αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight. Cell Mol Life Sci 2019;76:4705-24. [PMID: 31350618 DOI: 10.1007/s00018-019-03241-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 57 |
Millar SA, Anderson SI, O'Sullivan SE. Osteokines and the vasculature: a review of the in vitro effects of osteocalcin, fibroblast growth factor-23 and lipocalin-2. PeerJ 2019;7:e7139. [PMID: 31372314 DOI: 10.7717/peerj.7139] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 58 |
Christov M, Neyra JA, Gupta S, Leaf DE. Fibroblast Growth Factor 23 and Klotho in AKI. Semin Nephrol 2019;39:57-75. [PMID: 30606408 DOI: 10.1016/j.semnephrol.2018.10.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 59 |
Johnston JA, Nelson DR, Zhang L, Curtis SE, Voelker JR, Wetterau JR. Estimating the distribution of a novel clinical biomarker (FGF-23) in the US population using findings from a regional research registry. PLoS One 2019;14:e0218435. [PMID: 31246994 DOI: 10.1371/journal.pone.0218435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 60 |
Eisenga MF, De Jong MA, Van der Meer P, Leaf DE, Huls G, Nolte IM, Gaillard CAJM, Bakker SJL, De Borst MH. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. PLoS Med 2019;16:e1002818. [PMID: 31170159 DOI: 10.1371/journal.pmed.1002818] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 61 |
de Oliveira Neves FM, Araújo CB, de Freitas DF, Arruda BFT, de Macêdo Filho LJM, Salles VB, Meneses GC, Martins AMC, Libório AB. Fibroblast growth factor 23, endothelium biomarkers and acute kidney injury in critically-ill patients. J Transl Med 2019;17:121. [PMID: 30971270 DOI: 10.1186/s12967-019-1875-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 62 |
Bouma-de Krijger A, van Ittersum FJ, Hoekstra T, Ter Wee PM, Vervloet MG. Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3. Clin Kidney J 2019;12:678-85. [PMID: 31584563 DOI: 10.1093/ckj/sfz027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 63 |
Kim HK, Mizuno M, Vongpatanasin W. Phosphate, the forgotten mineral in hypertension. Curr Opin Nephrol Hypertens 2019;28:345-51. [PMID: 30883391 DOI: 10.1097/MNH.0000000000000503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 64 |
Picke AK, Campbell G, Napoli N, Hofbauer LC, Rauner M. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocr Connect 2019;8:R55-70. [PMID: 30772871 DOI: 10.1530/EC-18-0456] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 65 |
Avin KG, Vallejo JA, Chen NX, Wang K, Touchberry CD, Brotto M, Dallas SL, Moe SM, Wacker MJ. Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. Am J Physiol Endocrinol Metab 2018;315:E594-604. [PMID: 29558205 DOI: 10.1152/ajpendo.00343.2017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 66 |
Gruson D, Carbone V, Feracin B, Ahn SA, Rousseau MF. Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients. Clin Biochem 2018;61:47-9. [PMID: 30205090 DOI: 10.1016/j.clinbiochem.2018.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 67 |
Pi M, Ye R, Han X, Armstrong B, Liu X, Chen Y, Sun Y, Quarles LD. Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II. Sci Rep 2018;8:12398. [PMID: 30120363 DOI: 10.1038/s41598-018-30098-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 68 |
Verkaik M, Juni RP, van Loon EPM, van Poelgeest EM, Kwekkeboom RFJ, Gam Z, Richards WG, Ter Wee PM, Hoenderop JG, Eringa EC, Vervloet MG; NIGRAM Consortium. FGF23 impairs peripheral microvascular function in renal failure. Am J Physiol Heart Circ Physiol 2018;315:H1414-24. [PMID: 30028196 DOI: 10.1152/ajpheart.00272.2018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 69 |
Stöhr R, Schuh A, Heine GH, Brandenburg V. FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator? Front Endocrinol (Lausanne) 2018;9:351. [PMID: 30013515 DOI: 10.3389/fendo.2018.00351] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 70 |
Tanaka K, Salunya T, Motomiya Y, Motomiya Y, Oyama Y, Yamakuchi M, Maruyama I. Decreased Expression of Thrombomodulin in Endothelial Cells by Fibroblast Growth Factor-23/α-Klotho. Ther Apher Dial 2017;21:395-404. [PMID: 28834363 DOI: 10.1111/1744-9987.12524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 71 |
Georgianos PI, Pikilidou MI, Liakopoulos V, Balaskas EV, Zebekakis PE. Arterial stiffness in end-stage renal disease-pathogenesis, clinical epidemiology, and therapeutic potentials. Hypertens Res 2018;41:309-19. [PMID: 29531291 DOI: 10.1038/s41440-018-0025-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 72 |
Leaf DE, Siew ED, Eisenga MF, Singh K, Mc Causland FR, Srivastava A, Ikizler TA, Ware LB, Ginde AA, Kellum JA, Palevsky PM, Wolf M, Waikar SS. Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. Clin J Am Soc Nephrol 2018;13:531-41. [PMID: 29519954 DOI: 10.2215/CJN.10810917] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 73 |
Rossi GP, Seccia TM, Barton M, Danser AJ, de Leeuw PW, Dhaun N, Rizzoni D, Rossignol P, Ruilope L, van den Meiracker AH, Ito S, Hasebe N, Webb DJ. Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension. Journal of Hypertension 2018;36:462-71. [DOI: 10.1097/hjh.0000000000001600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 74 |
Tranæus Lindblad Y, Olauson H, Vavilis G, Hammar U, Herthelius M, Axelsson J, Bárány P. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study. Pediatr Nephrol 2018;33:147-57. [PMID: 28795324 DOI: 10.1007/s00467-017-3766-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 75 |
Erben RG. Fibroblast Growth Factor 23. Encyclopedia of Signaling Molecules 2018. [DOI: 10.1007/978-1-4614-6438-9_101993-1] [Reference Citation Analysis]
|
| 76 |
Erben RG. Pleiotropic Actions of FGF23. Toxicol Pathol 2017;45:904-10. [PMID: 29096595 DOI: 10.1177/0192623317737469] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 77 |
Fujii H, Kono K, Nakai K, Goto S, Nishii T, Kono A, Nishi S. Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis. Calcif Tissue Int 2018;102:310-20. [PMID: 29058057 DOI: 10.1007/s00223-017-0347-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 78 |
. Endocrine Regulation of Phosphate Homeostasis. Dietary Phosphorus: Health, Nutrition, and Regulatory Aspects 2017. [DOI: 10.1201/9781315119533-8] [Reference Citation Analysis]
|
| 79 |
Papagianni A. Fibroblast Growth Factor-23: A Novel Biomarker for Cardiovascular Disease in Chronic Kidney Disease Patients. PRILOZI 2017;38:19-27. [DOI: 10.1515/prilozi-2017-0018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 80 |
Matkar PN, Ariyagunarajah R, Leong-Poi H, Singh KK. Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis. Biomolecules 2017;7:E74. [PMID: 28974056 DOI: 10.3390/biom7040074] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 81 |
Krishnasamy R, Tan SJ, Hawley CM, Johnson DW, Stanton T, Lee K, Mudge DW, Campbell S, Elder GJ, Toussaint ND, Isbel NM. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrol 2017;18:281. [PMID: 28870151 DOI: 10.1186/s12882-017-0705-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 82 |
Grabner A, Schramm K, Silswal N, Hendrix M, Yanucil C, Czaya B, Singh S, Wolf M, Hermann S, Stypmann J, Di Marco GS, Brand M, Wacker MJ, Faul C. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci Rep 2017;7:1993. [PMID: 28512310 DOI: 10.1038/s41598-017-02068-6] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 83 |
Afsar B, Rossignol P, van Heerebeek L, Paulus WJ, Damman K, Heymans S, van Empel V, Sag A, Maisel A, Kanbay M. Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Fail Rev 2017;22:765-73. [DOI: 10.1007/s10741-017-9619-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 84 |
Chung CP, Chang YC, Ding Y, Lim K, Liu Q, Zhu L, Zhang W, Lu TS, Molostvov G, Zehnder D, Hsiao LL. α-Klotho expression determines nitric oxide synthesis in response to FGF-23 in human aortic endothelial cells. PLoS One 2017;12:e0176817. [PMID: 28463984 DOI: 10.1371/journal.pone.0176817] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 85 |
Haffner D, Leifheit-Nestler M. Extrarenal effects of FGF23. Pediatr Nephrol 2017;32:753-65. [PMID: 27704252 DOI: 10.1007/s00467-016-3505-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 86 |
Mencke R, Hillebrands JL; NIGRAM consortium. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology. Ageing Res Rev 2017;35:124-46. [PMID: 27693241 DOI: 10.1016/j.arr.2016.09.001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 87 |
Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wiecek A, London G; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association – European Dialysis Transplantation Association (ERA-EDTA). The systemic nature of CKD. Nat Rev Nephrol 2017;13:344-58. [PMID: 28435157 DOI: 10.1038/nrneph.2017.52] [Cited by in Crossref: 175] [Cited by in F6Publishing: 179] [Article Influence: 29.2] [Reference Citation Analysis]
|
| 88 |
Qin Z, Liu X, Song M, Zhou Q, Yu J, Zhou B, Wu Y, He Y, Huang L. Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies. Atherosclerosis 2017;261:1-11. [PMID: 28411494 DOI: 10.1016/j.atherosclerosis.2017.03.042] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 89 |
Kunasegaran T, Mustafa MR, Achike FI, Murugan DD. Quercetin and pioglitazone synergistically reverse endothelial dysfunction in isolated aorta from fructose-streptozotocin (F-STZ)-induced diabetic rats. European Journal of Pharmacology 2017;799:160-70. [DOI: 10.1016/j.ejphar.2017.02.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 90 |
Sharaf El Din UA, Salem MM, Abdulazim DO. Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review. J Adv Res 2017;8:271-8. [PMID: 28337344 DOI: 10.1016/j.jare.2017.02.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 91 |
Yamada S, Tsuruya K, Tokumoto M, Yoshida H, Tatsumoto N, Ooboshi H, Kitazono T. Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis. Ther Apher Dial 2017;21:71-8. [PMID: 28078749 DOI: 10.1111/1744-9987.12478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 92 |
Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf) 2017;219:22-96. [PMID: 26706498 DOI: 10.1111/apha.12646] [Cited by in Crossref: 465] [Cited by in F6Publishing: 490] [Article Influence: 77.5] [Reference Citation Analysis]
|
| 93 |
Shimosawa T, Jimbo R. Phosphorus and Mortality: Do We Have the Panacea? Cardio-Nephrology 2017. [DOI: 10.1007/978-3-319-56042-7_7] [Reference Citation Analysis]
|
| 94 |
Hu X, Ma X, Luo Y, Xu Y, Xiong Q, Pan X, Bao Y, Jia W. Contribution of fibroblast growth factor 23 to Framingham risk score for identifying subclinical atherosclerosis in Chinese men. Nutr Metab Cardiovasc Dis 2017;27:147-53. [PMID: 28017526 DOI: 10.1016/j.numecd.2016.11.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 95 |
Lu X, Hu MC. Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. Kidney Dis (Basel) 2017;3:15-23. [PMID: 28785560 DOI: 10.1159/000452880] [Cited by in Crossref: 104] [Cited by in F6Publishing: 111] [Article Influence: 14.9] [Reference Citation Analysis]
|
| 96 |
Hu X, Ma X, Luo Y, Xu Y, Xiong Q, Pan X, Bao Y, Jia W. Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes. Sci Rep 2016;6:34696. [PMID: 27698482 DOI: 10.1038/srep34696] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 97 |
Yamada H, Kuro-O M, Hara K, Ueda Y, Kusaka I, Kakei M, Ishikawa SE. The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease. PLoS One 2016;11:e0160782. [PMID: 27504998 DOI: 10.1371/journal.pone.0160782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 98 |
Richter B, Haller J, Haffner D, Leifheit-Nestler M. Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch 2016;468:1621-35. [PMID: 27448998 DOI: 10.1007/s00424-016-1858-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 99 |
Manrique C, Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Martinez-Lemus LA, Ramirez-Perez FI, Klein T, Meininger GA, DeMarco VG. Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. Cardiovasc Diabetol 2016;15:94. [PMID: 27391040 DOI: 10.1186/s12933-016-0414-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 100 |
Katoh M. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med 2016;38:3-15. [PMID: 27245147 DOI: 10.3892/ijmm.2016.2620] [Cited by in Crossref: 219] [Cited by in F6Publishing: 229] [Article Influence: 31.3] [Reference Citation Analysis]
|
| 101 |
Wacker MJ, Touchberry CD, Silswal N, Brotto L, Elmore CJ, Bonewald LF, Andresen J, Brotto M. Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets. Front Physiol 2016;7:173. [PMID: 27242547 DOI: 10.3389/fphys.2016.00173] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 102 |
Erben RG. Update on FGF23 and Klotho signaling. Mol Cell Endocrinol 2016;432:56-65. [PMID: 27178987 DOI: 10.1016/j.mce.2016.05.008] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 103 |
Cao C, Hu JX, Dong YF, Zhan R, Li P, Su H, Peng Q, Wu T, Huang X, Sun WH, Wu QH, Cheng XS. Association of Endothelial and Mild Renal Dysfunction With the Severity of Left Ventricular Hypertrophy in Hypertensive Patients. Am J Hypertens 2016;29:501-8. [PMID: 26232035 DOI: 10.1093/ajh/hpv128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 104 |
Zoccali C, Torino C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Ghiadoni L, Thadhani R, Tripepi G, Mallamaci F. Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients. Nutr Metab Cardiovasc Dis 2016;26:581-9. [PMID: 27113290 DOI: 10.1016/j.numecd.2016.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 105 |
Neyra JA, Hu MC. αKlotho and Chronic Kidney Disease. Vitam Horm 2016;101:257-310. [PMID: 27125746 DOI: 10.1016/bs.vh.2016.02.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 106 |
Kunasegaran T, Mustafa MR, Murugan DD, Achike FI. The bioflavonoid quercetin synergises with PPAR-γ agonist pioglitazone in reducing angiotensin-II contractile effect in fructose-streptozotocin induced diabetic rats. Biochimie 2016;125:131-9. [PMID: 27012965 DOI: 10.1016/j.biochi.2016.03.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 107 |
Dounousi E, Torino C, Pizzini P, Cutrupi S, Panuccio V, D'Arrigo G, Abd ElHafeez S, Tripepi G, Mallamaci F, Zoccali C. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients. Eur J Clin Invest 2016;46:234-41. [PMID: 26728476 DOI: 10.1111/eci.12588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 108 |
Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van Heerebeek L, Hillege HL, Lam CS, Navis G, Voors AA. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 2016;18:588-98. [PMID: 26861140 DOI: 10.1002/ejhf.497] [Cited by in Crossref: 180] [Cited by in F6Publishing: 191] [Article Influence: 25.7] [Reference Citation Analysis]
|
| 109 |
Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. Circulation 2016;133:518-36. [DOI: 10.1161/circulationaha.115.018713] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 110 |
Silva AP, Mendes F, Fragoso A, Jeronimo T, Pimentel A, Gundlach K, Büchel J, Santos N, Neves PL. Altered serum levels of FGF-23 and magnesium are independent risk factors for an increased albumin-to-creatinine ratio in type 2 diabetics with chronic kidney disease. J Diabetes Complications 2016;30:275-80. [PMID: 26750742 DOI: 10.1016/j.jdiacomp.2015.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 111 |
Nilsson I, Norenstedt S, Granath F, Zedenius J, Pernow Y, Larsson TE. FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery 2016;159:211-7. [DOI: 10.1016/j.surg.2015.06.057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 112 |
Freedman BI, Divers J, Russell GB, Palmer ND, Bowden DW, Carr JJ, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Langefeld CD, Hruska KA, Register TC. Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus. Am J Nephrol 2015;42:391-401. [PMID: 26693712 DOI: 10.1159/000443241] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 113 |
Silswal N, Parelkar N, Andresen J, Wacker MJ. Restoration of Endothelial Function in Pparα (-/-) Mice by Tempol. PPAR Res 2015;2015:728494. [PMID: 26649033 DOI: 10.1155/2015/728494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 114 |
Dounousi E, Torino C, Pizzini P, Cutrupi S, Panuccio V, D'Arrigo G, Abd ElHafeez S, Tripepi G, Mallamaci F, Zoccali C. Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients. Nutr Metab Cardiovasc Dis 2016;26:80-3. [PMID: 26712271 DOI: 10.1016/j.numecd.2015.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 115 |
Neyra JA, Moe OW, Hu MC. Fibroblast growth factor 23 and acute kidney injury. Pediatr Nephrol 2015;30:1909-18. [PMID: 25480729 DOI: 10.1007/s00467-014-3006-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 116 |
Lee G, Krishnasamy R, Hawley CM, Johnson DW. The impact of fibroblast growth factor-23 on the cardiovascular system in chronic kidney disease. Expert Rev Endocrinol Metab 2015;10:565-8. [PMID: 30289031 DOI: 10.1586/17446651.2015.1079124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 117 |
Georgianos PI, Sarafidis PA, Liakopoulos V. Arterial Stiffness: A Novel Risk Factor for Kidney Injury Progression? Am J Hypertens 2015;28:958-65. [PMID: 25687879 DOI: 10.1093/ajh/hpv004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 118 |
Zelenchuk LV, Hedge AM, Rowe PS. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif. Bone 2015;79:131-42. [PMID: 26051469 DOI: 10.1016/j.bone.2015.05.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 119 |
Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A, Go A, Lash J, Kusek J, Grunwald J, Wolf M; CRIC Study Investigators. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study. Nephrol Dial Transplant 2015;30:1534-41. [PMID: 25910495 DOI: 10.1093/ndt/gfv123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
